Comparative study reveals comparable cardiovascular safety between dupilumab and omalizumab in severe asthma, suggesting similar heart-related risk profiles across these biologics.
Summary Cardiovascular safety comparisons among asthma biologics remain limited. Dupilumab and omalizumab showed comparable cardiovascular outcomes in severe asthma.
No takes yet. Share an insight, caveat, or question.
Shih et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: